Home > Insider Trading > Filing (0000904454-13-001123)

Filing Details

Accession Number:: 0000904454-13-001123
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2013-10-29 20:07:11
Reporting Period:: 2013-10-25

Filing Date:: 2013-10-29
Accepted Time:: 2013-10-29 20:07:11
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1262104	Mei Pharma Inc.	MEIP	Pharmaceutical Preparations (2834)	510407811

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1398936	Vivo Ventures V Affiliates Fund, L.p.	575 High Street, Suite 201 Palo Alto CA 94301	No	No	Yes	No
1398937	Vivo Ventures Fund V, L.p.	575 High Street, Suite 201 Palo Alto CA 94301	No	No	Yes	No
1399028	Vivo Ventures V, Llc	575 High Street, Suite 201 Palo Alto CA 94301	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2013-10-25	15,100	$8.20	182,322	No	4	S	Indirect	See footnote
Common Stock	Disposition	2013-10-28	2,263	$8.30	180,059	No	4	S	Indirect	See footnote
Common Stock	Disposition	2013-10-29	44	$8.27	180,015	No	4	S	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote

Footnotes

Includes 180,452 shares held of record by Vivo Ventures Fund V, L.P., and 1,870 shares held of record by Vivo Ventures V Affiliates Fund, L.P. (together, the "Vivo V Funds"). Vivo Ventures V, LLC (the "Vivo V GP"), as the sole general partner of both of the Vivo V Funds, may be deemed to beneficially own the Common Stock of the Issuer owned by the Vivo V Funds. Vivo V GP disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein..
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.25 to $8.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
Includes 178,212 shares held of record by Vivo Ventures Fund V, L.P., and 1,847 shares held of record by Vivo Ventures V Affiliates Fund, L.P. (together, the "Vivo V Funds"). Vivo Ventures V, LLC (the "Vivo V GP"), as the sole general partner of both of the Vivo V Funds, may be deemed to beneficially own the Common Stock of the Issuer owned by the Vivo V Funds. Vivo V GP disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.25 to $8.30 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
Includes 178,169 shares held of record by Vivo Ventures Fund V, L.P., and 1,846 shares held of record by Vivo Ventures V Affiliates Fund, L.P. (together, the "Vivo V Funds"). Vivo Ventures V, LLC (the "Vivo V GP"), as the sole general partner of both of the Vivo V Funds, may be deemed to beneficially own the Common Stock of the Issuer owned by the Vivo V Funds. Vivo V GP disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein.